systemic ALK-positive anaplastic large cell lymphoma
GPTKB entity
Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
leukemia |
| gptkbp:affects |
lymph nodes
extranodal sites |
| gptkbp:commonIn |
children
young adults |
| gptkbp:expressedIn |
nucleophosmin-ALK fusion protein
|
| gptkbp:firstDescribed |
1995
|
| gptkbp:hasGeneticAlteration |
t(2;5)(p23;q35) translocation
|
| gptkbp:hasImmunophenotype |
CD30 positive
ALK positive EMA positive CD15 negative CD3 negative |
| gptkbp:hasMolecularFormula |
ALK gene rearrangement
|
| https://www.w3.org/2000/01/rdf-schema#label |
systemic ALK-positive anaplastic large cell lymphoma
|
| gptkbp:ICD-10_code |
C84.6
|
| gptkbp:marking |
gptkb:CD30
gptkb:ALK_protein |
| gptkbp:originatedIn |
gptkb:T-cell
|
| gptkbp:prognosis |
generally favorable
|
| gptkbp:subspecies |
gptkb:anaplastic_large_cell_lymphoma
|
| gptkbp:symptom |
fever
weight loss lymphadenopathy night sweats |
| gptkbp:treatment |
gptkb:brentuximab_vedotin
chemotherapy |
| gptkbp:bfsParent |
gptkb:ALK-positive_anaplastic_large_cell_lymphoma
|
| gptkbp:bfsLayer |
7
|